Recent 8-K filings for BIOA
Highest-materiality recent filing
BioAge Labs Q3 net loss $23.4M; IPO proceeds extend cash runway into 2029
- Net loss of $23.4M ($6.70/share) vs $14.6M ($8.74/share) in Q3 2023; R&D spend rose to $20.0M on Phase 2 STRIDES trial.
- Cash and cash equivalents at Sept. 30, 2024: $334.5M, with additional $27.6M from underwriter option in Oct. 2024.
-
BioAge Labs doses first patient in Phase 2 QUELL-DME trial of oral BGE-102 for DME
First participant dosed in QUELL-DME, a randomized, controlled Phase 2 trial of once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema.
-
BioAge Labs Q2 net loss $26.1M; dosed first participant in Phase 2 BGE-102 trial
Net loss $26.1M ($0.58/share) vs $21.6M ($0.60/share) in Q2 2025; R&D spend up $4.6M to $24.4M.
-
BioAge Labs shareholders elect three Class II directors, ratify KPMG at annual meeting
Class II directors elected: Patrick Enright (30.1M for, 1.2M withheld), James Healy (25.5M for, 5.8M withheld), Rekha Hemrajani (27.8M for, 3.4M withheld).
-
BioAge Labs Q1 net loss $22.3M; positive Phase 1 data for BGE-102 NLRP3 inhibitor
Net loss $22.3M ($0.52 diluted EPS) vs $12.9M ($0.36) in Q1 2025; R&D spend rose to $20.4M.
-
BioAge reports FY2025 net loss $80.6M; positive BGE-102 Phase 1 data; $132M offering
Positive interim Phase 1 data for BGE-102: 86% median hsCRP reduction, 93% of obese participants reached <2 mg/L.
-
BioAge Labs prices upsized $115M public offering of 5.9M shares at $19.50/share
5,897,435 shares offered at $19.50/share; gross proceeds ~$115M, net ~$107.6M.
-
BioAge Labs expands BGE-102 into diabetic macular edema; Phase 1b/2a trial planned mid-2026
Plans to initiate Phase 1b/2a proof-of-concept trial in DME in mid-2026; results expected mid-2027.
-
BioAge positive Phase 1 data for BGE-102: 86% hsCRP reduction, 93% normalized
BGE-102 achieved 86% median hsCRP reduction at Day 14 in obese patients with elevated baseline hsCRP; 93% reached <2 mg/L.
-
BioAge reports positive Phase 1 interim data for NLRP3 inhibitor BGE-102; 90-98% IL-1β suppression
BGE-102 well-tolerated across all doses (SAD: 10-120 mg; MAD: 60-120 mg); AEs mild/moderate, all resolved.
-
BioAge Q3 net loss $20.2M; first participant dosed in BGE-102 Phase 1 trial
Net loss of $20.2M ($0.56 EPS) vs $23.4M ($6.70) in Q3 2024; collaboration revenue $2.1M from Novartis deal.
-
BioAge Labs Q2 net loss $21.6M, cash $313.4M; BGE-102 Phase 1 on track for 2H 2025
Net loss $21.6M ($0.60/share) vs $13.6M loss in Q2 2024; R&D expenses rose to $19.8M.
-
BioAge Labs shareholders elect three Class I directors; ratify KPMG as auditor
Elected Class I directors Kristen Fortney, Eric Morgen, Vijay Pande to three-year terms expiring at 2028 annual meeting.
-
BioAge provides NLRP3 & APJ program timeline updates in corporate presentation
NLRP3 program: IND submission and Phase 1 SAD/MAD initiation planned for mid-2025; initial SAD data expected by end of 2025.
-
BioAge Labs Q1 net loss $12.9M; cash $335.1M; BGE-102 Phase 1 data expected 2H25
Net loss of $12.9M ($0.36 diluted EPS) vs $13.0M loss in Q1 2024; no revenue reported.
-
BioAge Labs FY2024 net loss $71.1M; advances NLRP3 inhibitor BGE-102; discontinues azelaprag
Net loss of $71.1M ($6.63/share) for FY2024; cash $354.3M expected to fund operations through 2029.
-
BioAge Labs Q3 net loss $23.4M; IPO proceeds extend cash runway into 2029
Net loss of $23.4M ($6.70/share) vs $14.6M ($8.74/share) in Q3 2023; R&D spend rose to $20.0M on Phase 2 STRIDES trial.
-
BioAge Labs sells 588,888 shares to Sofinnova at $18 in private placement concurrent with IPO
Private placement of 588,888 shares to existing stockholder Sofinnova at IPO price of $18.00/share, raising $10.6 million.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material